Iveric Bio Announces Agreement For Up To $250 Million In Non-Dilutive Debt Financing With Hercules Capital And Silicon Valley Bank
Iveric Bio Announces Agreement For Up To $250 Million In Non-Dilutive Debt Financing With Hercules Capital And Silicon Valley Bank
07/26/22, 10:38 AM
Location
parsippany
Industry
therapeutics
biotechnology
health care
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that it has entered into a term loan debt financing facility with Hercules Capital, Inc. (NYSE: HTGC) and Silicon Valley Bank providing the Company with total borrowing capacity of up to $250 million in non-dilutive debt financing.
Company Info
Location
parsippany, new jersey, united states
Additional Info
Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.